Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929275 | 1.00 | NR1H2 (0.46) | NR1H2PDE4BNAMPTUSP2SMN1; SMN2 | |
| SCHEMBL3370045 | 1.00 | NR1H2 (0.46) | NR1H2PDE4BNAMPTUSP2SMN1; SMN2 | |
| SCHEMBL3375201 | 0.85 | NR1H2 (0.36) | NR1H2PDE4BNAMPTMAPTMEN1 | |
| SCHEMBL2936643 | 0.85 | NR1H2 (0.36) | NR1H2PDE4BNAMPTMAPTMEN1 | |
| SCHEMBL3370015 | 0.83 | NR1H2 (0.35) | NR1H2NAMPTMAPTMEN1ALDH1A1 | |
| SCHEMBL3252631 | 0.80 | NR1H2 (0.36) | NR1H2PDE4BMAPTMEN1ALDH1A1 | |
| SCHEMBL3374586 | 0.80 | NR1H2 (0.37) | NR1H2NAMPTUSP2SMN1; SMN2MAPT | |
| SCHEMBL2930145 | 0.80 | NR1H2 (0.37) | NR1H2NAMPTUSP2SMN1; SMN2MAPT | |
| SCHEMBL1015271 | 0.79 | PDE4B (0.44) | NR1H2PDE4BNAMPTUSP2SMN1; SMN2 | |
| SCHEMBL1014216 | 0.78 | NR1H2 (0.65) | NR1H2PDE4BNAMPTUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272858-A2 | HCV inhibitors comprising beta amino acids and their uses | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| EP-2007787-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| WO-2007121124-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | NR1H2 531/4885PDE4B 3578/4885NAMPT 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.